The effect of pharmacotherapy on prostate volume, prostate perfusion and PSA (Prostate Morphometric Parameters) in patients with Lower Urinary Tract Symptoms (LUTS) and Benign Prostatic Obstruction (BPO)? A systematic review and meta-analysis

Sakalis, Vasileios; Gkotsi, A.; Guillamier, S.; Tsafrakidis, Petros; Ierides, S.; Zarkadoulias, Adam; Charpidou, D.; Apostolidis, Apostolos

doi:10.1016/s2666-1683(20)32995-5

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The American Urological Association suggested expecting approximately a 50% decrease in serum PSA among men using 5-ARIs (4,61). These guidelines are in line with a 2021 systematic review and meta-analysis by Sakalis et al, observing a comparable reduction in PSA when compared to dutasteride (62). However, Sakalis et al observed finasteride reduced PSA levels by −0.62 [95% CI: −0.71 to 0.56], suggesting an underestimation when compared to conventional teaching.…”

Section: Prostate Cancersupporting

confidence: 80%

5-alpha reductase inhibitors use in prostatic disease and beyond

Chislett¹,

Chen²,

Perera³

et al. 2023

Transl Androl Urol

View full text Add to dashboard Cite

in use today (1,2). Their effect relies on the inhibition of the 5-alpha reductase (5α-reductase) enzyme which aids in the conversion of testosterone to dihydrotestosterone (DHT) (3).Since its introduction, the clinical indication for 5-ARIs has grown from BPH to include androgenetic alopecia (AGA) and hirsutism (1). As more pathological processes are identified as being mediated by DHT, the clinical

show abstract

Section: Prostate Cancersupporting

confidence: 80%

5-alpha reductase inhibitors use in prostatic disease and beyond

Chislett¹,

Chen²,

Perera³

et al. 2023

Transl Androl Urol

View full text Add to dashboard Cite

show abstract

“…Before drug treatment, urodynamic examination should be performed on the patient to determine the type of bladder disorder, and then an appropriate drug would be selected according to the test results. The adverse reactions of drug therapy will increase with the increase of drug dose, and about 25% of urinary tract patients with benign prostatic obstruction stop taking drugs due to intolerance[ 13 ].…”

Section: Rehabilitation Nursing Measuresmentioning

confidence: 99%

Rehabilitation care of patients with neurogenic bladder after spinal cord injury: A literature review

Xiang¹,

Li²,

Xie³

et al. 2023

World J Clin Cases

View full text Add to dashboard Cite

This article reviews the research progress of rehabilitation treatment and nursing care of patients with neurogenic bladder after spinal cord injury, in order to provide reference for the rehabilitation treatment and nursing care of patients. We reviewed recent medical literature on patients with neurogenic bladder, focusing on neurogenic bladder caused by spinal cord injury. We analyzed 30 recent of publications in patients with neurogenic bladder after spinal cord injury, in addition to reviewing and evaluating the commonly used rehabilitation nursing methods for neurogenic bladder. Psychological counseling is a vital aspect which cannot be neglected in the process of neurogenic bladder rehabilitation. Hitherto, the commonly used drug and surgical treatments may have negatively impacted the mental health of patients in varying degrees. However, in clinical practice, applying intermittent catheterization in patients who have neurogenic bladder with spinal cord injury may help improve patients’ life quality, mitigate psychological burden, and reduce negative emotions.

show abstract

“…Adding complexity to this landscape is the diversity of clinical outcomes observed in BPH patients with prostatic inflammation (13,14). Studies have reported varying degrees of symptom severity, response to standard pharmacotherapy, and progression to acute urinary retention or the need for surgical intervention among these individuals (15,16). This variability features the heterogeneity of BPH as a clinical entity and the multifactorial nature of its progression, which may be influenced by factors such as genetic predispositions, environmental exposures, and lifestyle choices (17).…”

Section: Introductionmentioning

confidence: 99%

Effects of Prostatic Inflammation on Clinical Outcomes in Patients with Benign Prostate Hyperplasia

Mehmood,

Ayaz,

Kakakhel

2024

JHRR

View full text Add to dashboard Cite

Background: Benign prostate hyperplasia (BPH), a non-cancerous enlargement of the prostate gland, prevalently impacts the aging male population, often disrupting the quality of life with its accompanying urinary symptoms. The intersection between BPH and prostatic inflammation has emerged as a focal point in urological research, with inflammation speculated to exacerbate BPH progression and symptoms. Understanding this relationship is pivotal in refining therapeutic approaches and improving patient outcomes. Objective: This study aimed to elucidate the effects of prostatic inflammation on the clinical outcomes of patients with BPH, focusing on symptom progression, treatment efficacy, and long-term complications. Methods: This Study Conducted at Gajju Khan Medical College Swabi, KPK, Pakistan, in the duration from January, 2023 to June, 2023. This prospective cohort study involved 126 men with BPH, categorized into two groups based on the presence (n=63) or absence (n=63) of prostatic inflammation. Data were collected over three years, with assessments including demographic information, clinical histories, and prostate examinations. Primary outcomes measured were the progression of BPH symptoms, urinary function, and prostate size. Secondary outcomes included quality of life, acute urinary retention, the need for surgical intervention, medication efficacy, and long-term complications. Statistical analyses employed included Chi-square tests, t-tests, and ANOVA, with SPSS software. Results: The group with prostatic inflammation showed significantly more severe symptom progression (p < 0.01), impaired urinary function (p < 0.01), and increased prostate size (p < 0.01) compared to the non-inflamed group. Secondary outcomes also favored the non-inflamed group with better quality of life scores (75.2 ± 5.2 vs. 78.8 ± 4.8, p < 0.01), lower rates of acute urinary retention (20.3% vs. 15.5%, p < 0.01). Conclusion: Prostatic inflammation significantly worsens the clinical outcomes of BPH, affecting symptom progression, treatment response, and the likelihood of long-term complications. These findings suggest the need for integrated therapeutic strategies that address both BPH and prostatic inflammation to optimize patient care.

show abstract

The effect of pharmacotherapy on prostate volume, prostate perfusion and PSA (Prostate Morphometric Parameters) in patients with Lower Urinary Tract Symptoms (LUTS) and Benign Prostatic Obstruction (BPO)? A systematic review and meta-analysis

Cited by 3 publications

References 0 publications

5-alpha reductase inhibitors use in prostatic disease and beyond

5-alpha reductase inhibitors use in prostatic disease and beyond

Rehabilitation care of patients with neurogenic bladder after spinal cord injury: A literature review

Effects of Prostatic Inflammation on Clinical Outcomes in Patients with Benign Prostate Hyperplasia

Contact Info

Product

Resources

About